{"id":33611,"date":"2024-05-24T06:58:03","date_gmt":"2024-05-24T12:58:03","guid":{"rendered":"https:\/\/brakkeconsulting.com\/?p=33611"},"modified":"2024-05-24T06:58:03","modified_gmt":"2024-05-24T12:58:03","slug":"brakke-viewpoint-may-24-2024","status":"publish","type":"post","link":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-may-24-2024\/","title":{"rendered":"\u30d6\u30e9\u30c3\u30b1\u8996\u70b9 2024\u5e745\u670824\u65e5"},"content":{"rendered":"<p>\u4eca\u9031\u3001\u79c1\u305f\u3061\u306f\u5e74\u6b21\u5831\u544a\u66f8\u306e\u6700\u65b0\u7248\u3092\u767a\u884c\u3057\u307e\u3057\u305f\u3002 <strong><em>\u75bc\u75db\u7ba1\u7406\u88fd\u54c1<\/em><\/strong> \u5831\u544a\u66f8\u306b\u3088\u308b\u3068\u3001\u3053\u306e\u5e02\u5834\u30bb\u30b0\u30e1\u30f3\u30c8\u306f\u3001\u6628\u5e74 11 \u6708\u306b Zoetis \u793e\u304c\u95a2\u7bc0\u708e\u6cbb\u7642\u7528\u306e\u6bce\u6708\u6295\u4e0e\u3059\u308b\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u6ce8\u5c04\u5264 Librela \u3092\u767a\u58f2\u3057\u305f\u3053\u3068\u3001\u307e\u305f\u30012022 \u5e74\u5f8c\u534a\u306b\u306f\u732b\u7528\u540c\u7b49\u85ac Solensia \u3092\u767a\u58f2\u3057\u305f\u3053\u3068\u304b\u3089\u3001\u975e\u5e38\u306b\u8208\u5473\u6df1\u3044\u6642\u671f\u3092\u8fce\u3048\u3066\u3044\u308b\u3002<\/p>\n<p>\u3053\u306e\u65b0\u3057\u3044\u7a2e\u985e\u306e\u93ae\u75db\u85ac\u306f\u3001\u6162\u6027\u75bc\u75db\u306e\u6cbb\u7642\u306b\u9769\u547d\u3092\u8d77\u3053\u3059\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u307b\u3068\u3093\u3069\u306e\u7363\u533b\u5e2b\u306f\u3001\u3059\u3067\u306b\u5909\u5f62\u6027\u95a2\u7bc0\u75c7\u306e\u60a3\u8005\u306b\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u3092\u4f7f\u7528\u3057\u3066\u3044\u307e\u3059\u3002\u3057\u304b\u3057\u3001\u3069\u306e\u304f\u3089\u3044\u306e\u983b\u5ea6\u3067\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u3092\u4f7f\u7528\u3057\u3066\u3044\u308b\u306e\u3067\u3057\u3087\u3046\u304b\u3002\u5358\u72ec\u306e\u6cbb\u7642\u306a\u306e\u3067\u3057\u3087\u3046\u304b\u3001\u305d\u308c\u3068\u3082\u8907\u5408\u7684\u30d7\u30ed\u30c8\u30b3\u30eb\u306e\u4e00\u90e8\u306a\u306e\u3067\u3057\u3087\u3046\u304b\u3002Librela \u306f\u3001\u5909\u5f62\u6027\u95a2\u7bc0\u75c7\u306e\u6cbb\u7642\u306b\u304a\u3051\u308b NSAID \u306e\u4f7f\u7528\u3092\u5b8c\u5168\u306b\u7f6e\u304d\u63db\u3048\u308b\u306e\u3067\u3057\u3087\u3046\u304b\u3002Solensia \u306f\u30011990 \u5e74\u4ee3\u306b\u767a\u58f2\u3055\u308c\u305f Rimadyl \u306e\u3088\u3046\u306b\u3001\u65b0\u3057\u3044\u5e02\u5834\u3092\u5275\u51fa\u3057\u3066\u3044\u308b\u306e\u3067\u3057\u3087\u3046\u304b\u3002<\/p>\n<p>\u5f53\u793e\u306e\u75bc\u75db\u7ba1\u7406\u88fd\u54c1\u30ec\u30dd\u30fc\u30c8\u3067\u306f\u3001350 \u540d\u306e\u7363\u533b\u5e2b\u306b\u3088\u308b\u8abf\u67fb\u304b\u3089\u306e\u76f4\u63a5\u30d5\u30a3\u30fc\u30c9\u30d0\u30c3\u30af\u3068\u30012024 \u5e74 4 \u6708\u6642\u70b9\u306e PIMS \u30d9\u30fc\u30b9\u306e\u8abf\u5264\u30c7\u30fc\u30bf\u3092\u57fa\u306b\u3001\u3053\u308c\u3089\u306e\u8cea\u554f\u3084\u305d\u306e\u4ed6\u306e\u8cea\u554f\u306b\u7b54\u3048\u3066\u3044\u307e\u3059\u3002\u8cb4\u793e\u304c\u30da\u30c3\u30c8\u306e\u75bc\u75db\u7ba1\u7406\u5e02\u5834\u306b\u643a\u308f\u3063\u3066\u3044\u308b\u5834\u5408\u3001\u3053\u306e\u30ec\u30dd\u30fc\u30c8\u306e\u8cb4\u91cd\u306a\u6d1e\u5bdf\u3092\u898b\u9003\u3055\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002<\/p>\n<p><em>\u30ea\u30f3\u30fb\u30d5\u30a9\u30f3\u30c9\u30f3<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>\u4eca\u9031\u3001\u79c1\u305f\u3061\u306f\u5e74\u6b21\u75bc\u75db\u7ba1\u7406\u88fd\u54c1\u30ec\u30dd\u30fc\u30c8\u306e\u6700\u65b0\u7248\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u6628\u5e7411\u6708\u306b\u30be\u30a8\u30c6\u30a3\u30b9\u793e\u304c\u767a\u58f2\u3057\u305f\u5909\u5f62\u6027\u95a2\u7bc0\u75c7\u6cbb\u7642\u7528\u306e\u67081\u56de\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u6ce8\u5c04\u5264\u300c\u30ea\u30d6\u30ec\u30e9\u300d\u3001\u305d\u3057\u30662022\u5e74\u5f8c\u534a\u306b\u306f\u732b\u7528\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u6ce8\u5c04\u5264\u300c\u30bd\u30ec\u30f3\u30b7\u30a2\u300d\u306e\u767a\u58f2\u306b\u3088\u308a\u3001\u3053\u306e\u5e02\u5834\u30bb\u30b0\u30e1\u30f3\u30c8\u306f\u4eca\u3001\u975e\u5e38\u306b\u8208\u5473\u6df1\u3044\u6642\u671f\u3092\u8fce\u3048\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u65b0\u3057\u3044\u30af\u30e9\u30b9\u306e\u75bc\u75db\u7ba1\u7406\u85ac\u306f\u3001\u6162\u6027\u75bc\u75db\u6cbb\u7642\u306b\u9769\u547d\u3092\u3082\u305f\u3089\u3059\u53ef\u80fd\u6027\u3092\u79d8\u3081\u3066\u3044\u307e\u3059\u3002\u591a\u304f\u306e\u7363\u533b\u5e2b\u306f\u3001\u3059\u3067\u306b\u5909\u5f62\u6027\u95a2\u7bc0\u75c7\u306e\u60a3\u8005\u306b\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u3092\u4f7f\u7528\u3057\u3066\u3044\u307e\u3059\u3002\u3057\u304b\u3057\u3001\u7363\u533b\u5e2b\u306f\u3069\u308c\u304f\u3089\u3044\u306e\u983b\u5ea6\u3067\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u3092\u4f7f\u7528\u3057\u3066\u3044\u308b\u306e\u3067\u3057\u3087\u3046\u304b\uff1f\u5358\u72ec\u6cbb\u7642\u3068\u3057\u3066\u4f7f\u7528\u3055\u308c\u3066\u3044\u308b\u306e\u3067\u3057\u3087\u3046\u304b\u3001\u305d\u308c\u3068\u3082\u30de\u30eb\u30c1\u30e2\u30fc\u30c0\u30eb\u30d7\u30ed\u30c8\u30b3\u30eb\u306e\u4e00\u90e8\u3068\u3057\u3066\u4f7f\u7528\u3055\u308c\u3066\u3044\u308b\u306e\u3067\u3057\u3087\u3046\u304b\uff1f\u30ea\u30d6\u30ec\u30e9\u306f\u3001\u5909\u5f62\u6027\u95a2\u7bc0\u75c7\u6cbb\u7642\u306b\u304a\u3051\u308bNSAIDs\u306e\u4f7f\u7528\u3092\u5b8c\u5168\u306b\u7f6e\u304d\u63db\u3048\u308b\u306e\u3067\u3057\u3087\u3046\u304b\uff1f\u30bd\u30ec\u30f3\u30b7\u30a2\u306f\u30011990\u5e74\u4ee3\u306b\u767a\u58f2\u3055\u308c\u305f\u30ea\u30de\u30b8\u30eb\u306e\u3088\u3046\u306b\u3001\u65b0\u305f\u306a\u5e02\u5834\u3092\u5275\u51fa\u3057\u3066\u3044\u308b\u306e\u3067\u3057\u3087\u3046\u304b\uff1f\u5f53\u793e\u306e\u75bc\u75db\u7ba1\u7406\u88fd\u54c1\u30ec\u30dd\u30fc\u30c8\u306f\u3001350\u540d\u306e\u7363\u533b\u5e2b\u3092\u5bfe\u8c61\u3068\u3057\u305f\u30a2\u30f3\u30b1\u30fc\u30c8\u8abf\u67fb\u304b\u3089\u306e\u76f4\u63a5\u30d5\u30a3\u30fc\u30c9\u30d0\u30c3\u30af\u3068\u30012024\u5e744\u6708\u6642\u70b9\u306ePIMS\u30d9\u30fc\u30b9\u306e\u8abf\u5264\u30c7\u30fc\u30bf\u306b\u57fa\u3065\u304d\u3001\u3053\u308c\u3089\u306e\u8cea\u554f\u3092\u306f\u3058\u3081\u3068\u3059\u308b\u69d8\u3005\u306a\u7591\u554f\u306b\u304a\u7b54\u3048\u3057\u307e\u3059\u3002\u30b3\u30f3\u30d1\u30cb\u30aa\u30f3\u30a2\u30cb\u30de\u30eb\u306e\u75bc\u75db\u7ba1\u7406\u5e02\u5834\u306b\u643a\u308f\u308b\u4f01\u696d\u3067\u3042\u308c\u3070\u3001\u3053\u306e\u30ec\u30dd\u30fc\u30c8\u306e\u8cb4\u91cd\u306a\u77e5\u898b\u3092\u305c\u3072\u304a\u898b\u9003\u3057\u306a\u304f\u3002\u30ea\u30f3\u30fb\u30d5\u30a9\u30f3\u30c9\u30f3<\/p>","protected":false},"author":19,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[43],"tags":[],"class_list":["post-33611","post","type-post","status-publish","format-standard","hentry","category-viewpoints"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>News from Brakke Consulting<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-may-24-2024\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News from Brakke Consulting\" \/>\n<meta property=\"og:description\" content=\"This week we published the latest edition of our annual Pain Management Products report.\u00a0 It\u2019s a fascinating time in the market segment, thanks to the launch last November of Zoetis\u2019 Librela, a monthly monoclonal antibody injection for treating osteoarthritis; and that of Solensia \u2013 the feline equivalent \u2013 in late 2022. This new class of pain management drugs has the potential to revolutionize the treatment of chronic pain.\u00a0 Most veterinarians are already using monoclonal antibodies in their osteoarthritis patients. But how often are they reaching for them?\u00a0 Are they stand-alone treatments, or part of a multi-modal protocol? Will Librela completely replace the use of NSAIDs in treating osteoarthritis? Is Solensia creating a new market, much like Rimadyl did so when it was launched in the 1990\u2019s? Our Pain Management Product report answers these questions and more, with direct feedback from our 350-veterinarian survey as well as PIMS-based dispensing data as of April 2024. If your company is part of the companion animal pain management market, you won\u2019t want to miss out on the valuable insights in this report. Lynn Fondon\" \/>\n<meta property=\"og:url\" content=\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-may-24-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Brakke Consulting Website\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-24T12:58:03+00:00\" \/>\n<meta name=\"author\" content=\"Amanda McDavid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Amanda McDavid\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/\"},\"author\":{\"name\":\"Amanda McDavid\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"headline\":\"Brakke Viewpoint May 24, 2024\",\"datePublished\":\"2024-05-24T12:58:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/\"},\"wordCount\":181,\"articleSection\":[\"Viewpoints\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/\",\"url\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/\",\"name\":\"News from Brakke Consulting\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#website\"},\"datePublished\":\"2024-05-24T12:58:03+00:00\",\"author\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"breadcrumb\":{\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/brakkeconsulting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brakke Viewpoint May 24, 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/brakkeconsulting.com\/#website\",\"url\":\"https:\/\/brakkeconsulting.com\/\",\"name\":\"Brakke Consulting Website\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/brakkeconsulting.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\",\"name\":\"Amanda McDavid\",\"url\":\"https:\/\/brakkeconsulting.com\/ja\/author\/amanda\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Brakke Consulting\u304b\u3089\u306e\u30cb\u30e5\u30fc\u30b9","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-may-24-2024\/","og_locale":"ja_JP","og_type":"article","og_title":"News from Brakke Consulting","og_description":"This week we published the latest edition of our annual Pain Management Products report.\u00a0 It\u2019s a fascinating time in the market segment, thanks to the launch last November of Zoetis\u2019 Librela, a monthly monoclonal antibody injection for treating osteoarthritis; and that of Solensia \u2013 the feline equivalent \u2013 in late 2022. This new class of pain management drugs has the potential to revolutionize the treatment of chronic pain.\u00a0 Most veterinarians are already using monoclonal antibodies in their osteoarthritis patients. But how often are they reaching for them?\u00a0 Are they stand-alone treatments, or part of a multi-modal protocol? Will Librela completely replace the use of NSAIDs in treating osteoarthritis? Is Solensia creating a new market, much like Rimadyl did so when it was launched in the 1990\u2019s? Our Pain Management Product report answers these questions and more, with direct feedback from our 350-veterinarian survey as well as PIMS-based dispensing data as of April 2024. If your company is part of the companion animal pain management market, you won\u2019t want to miss out on the valuable insights in this report. Lynn Fondon","og_url":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-may-24-2024\/","og_site_name":"Brakke Consulting Website","article_published_time":"2024-05-24T12:58:03+00:00","author":"Amanda McDavid","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"Amanda McDavid","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"1\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/#article","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/"},"author":{"name":"Amanda McDavid","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"headline":"Brakke Viewpoint May 24, 2024","datePublished":"2024-05-24T12:58:03+00:00","mainEntityOfPage":{"@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/"},"wordCount":181,"articleSection":["Viewpoints"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/","url":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/","name":"Brakke Consulting\u304b\u3089\u306e\u30cb\u30e5\u30fc\u30b9","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/#website"},"datePublished":"2024-05-24T12:58:03+00:00","author":{"@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"breadcrumb":{"@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/brakkeconsulting.com\/"},{"@type":"ListItem","position":2,"name":"Brakke Viewpoint May 24, 2024"}]},{"@type":"WebSite","@id":"https:\/\/brakkeconsulting.com\/#website","url":"https:\/\/brakkeconsulting.com\/","name":"Brakke Consulting\u306e\u30a6\u30a7\u30d6\u30b5\u30a4\u30c8","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/brakkeconsulting.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Person","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615","name":"\u30a2\u30de\u30f3\u30c0\u30fb\u30de\u30af\u30c7\u30a4\u30d3\u30c3\u30c9","url":"https:\/\/brakkeconsulting.com\/ja\/author\/amanda\/"}]}},"_links":{"self":[{"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/posts\/33611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/comments?post=33611"}],"version-history":[{"count":1,"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/posts\/33611\/revisions"}],"predecessor-version":[{"id":33613,"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/posts\/33611\/revisions\/33613"}],"wp:attachment":[{"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/media?parent=33611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/categories?post=33611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/tags?post=33611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}